Normann, L. S., Haugen, M. H., Hongisto, V., Aure, M. R., Leivonen, S., Kristensen, V. N., . . . Mælandsmo, G. M. (2023). High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. Public Library of Science (PLoS).
Chicago-čujuhus (17. p.)Normann, Lisa Svartdal, et al. High-throughput Screen in Vitro Identifies Dasatinib as a Candidate for Combinatorial Treatment with HER2-targeting Drugs in Breast Cancer. Public Library of Science (PLoS), 2023.
MLA-čujuhus (9. p.)Normann, Lisa Svartdal, et al. High-throughput Screen in Vitro Identifies Dasatinib as a Candidate for Combinatorial Treatment with HER2-targeting Drugs in Breast Cancer. Public Library of Science (PLoS), 2023.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.